Ghrelin Infusion in Humans Induces Acute Insulin Resistance and Lipolysis Independent of Growth Hormone Signaling
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE—Ghrelin is a gut-derived peptide and an endogenous ligand for the growth hormone (GH) secretagogue receptor. Exogenous ghrelin stimulates the release of GH (potently) and adrenocorticotropic hormone (ACTH) (moderately). Ghrelin is also orexigenic, but its impact on substrate metabolism is controversial. We aimed to study direct effects of ghrelin on substrate metabolism and insulin sensitivity in human subjects. RESEARCH DESIGN AND METHODS—Six healthy men underwent ghrelin (5 pmol · kg−1 · min−1) and saline infusions in a double-blind, cross-over study to study GH signaling proteins in muscle. To circumvent effects of endogenous GH and ACTH, we performed a similar study in eight hypopituitary adults but replaced with GH and hydrocortisone. The methods included a hyperinsulinemic-euglycemic clamp, muscle biopsies, microdialysis, and indirect calorimetry. RESULTS—In healthy subjects, ghrelin-induced GH secretion translated into acute GH receptor signaling in muscle. In the absence of GH and cortisol secretion, ghrelin acutely decreased peripheral, but not hepatic, insulin sensitivity together with stimulation of lipolysis. These effects occurred without detectable suppression of AMP-activated protein kinase phosphorylation (an alleged second messenger for ghrelin) in skeletal muscle. CONCLUSIONS—Ghrelin infusion acutely induces lipolysis and insulin resistance independently of GH and cortisol. We hypothesize that the metabolic effects of ghrelin provide a means to partition glucose to glucose-dependent tissues during conditions of energy shortage.
Overview
CoChat Summary
## TL;DR
This study found that ghrelin infusion in humans acutely increased lipolysis and reduced insulin-stimulated glucose disposal, even when GH and cortisol effects were controlled for in hypopituitary men. In healthy men, ghrelin also triggered endogenous GH release that led to STAT5 phosphorylation in skeletal muscle.
## Key findings
- In 6 healthy men, ghrelin infusion (5 pmol·kg⁻¹·min⁻¹) caused GH to peak at 60 min: 33.3 ± 8.0 μg/l vs. 1.1 ± 0.9 μg/l with saline (P = 0.008), and increased serum FFAs: 1.0 ± 0.1 μg/l vs. 0.4 ± 0.04 μg/l (P = 0.003).
- In those healthy subjects, skeletal muscle biopsies showed distinct STAT5 phosphorylation in all 6 subjects 30 min after the GH burst.
- In 8 hypopituitary men, ghrelin caused an 80% increase in FFAs to 0.62 ± 0.03 mmol/l at 120 min (P < 0.05) and raised plasma glucose to 6.1 ± 0.2 mmol/l at 120 min (P = 0.009).
- During the hyperinsulinemic-euglycemic clamp, ghrelin significantly decreased glucose infusion rate (GIR) (P < 0.01) and reduced the M value by ~60% (P < 0.001); it also reduced oxidative, nonoxidative, and total glucose disposal.
## Methods
- Two human infusion studies were conducted under ethics/GCP approval and registered as NCT00116025 and NCT00139945.
- Study 1: 6 healthy men (age 23 ± 1 years, BMI 23.5 ± 0.4 kg/m²) received saline or ghrelin infusion; a muscle biopsy was taken at 90 min.
- Study 2: 8 hypopituitary men (age 53 ± 4 years, BMI 31.6 ± 1.0 kg/m²) on stable GH and hydrocortisone replacement underwent a randomized double-blind cross-over design with 5-h saline or ghrelin infusions, followed by a hyperinsulinemic-euglycemic clamp from 120 to 300 min; outcomes included tracer-derived glucose kinetics, indirect calorimetry, microdialysis, hormone/metabolite assays, and skeletal muscle signaling by Western blot and PI3K assay.
## Limitations
- The paper states that in Study 2, muscle biopsies were obtained only in the basal period, which limits assessment of aberrations in insulin signaling pathways.
- The authors note that infusion of ghrelin does not imitate the secretory pattern of endogenous ghrelin.
- They also say the study was powered to detect effects on insulin sensitivity, so the lack of significant effects on lipid metabolism may be due to a β error.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
0 Valid · 0 Not valid · 18 Not checked · 44 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Plasma levels of norepinephrine and epinephrine were comparable on both study days”
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Energy expenditure, RQ, or lipid oxidation were not significantly affected by ghrelin in the basal or in the clamp period.”
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The increase in RQ (RQ clamp − RQ basal ) during the clamp, however, was larger in the saline study (0.07 ± 0.01 vs. 0.03 ± 0.01 [ghrelin], P = 0.03).”
plainn = 7 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Western blots performed on skeletal muscle biopsies revealed distinct STAT5 phosphorylation in all six subjects 30 min after the endogenous GH burst ( Fig. 3 ).”
plainstates a causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A significant elevation in serum FFA levels was recorded (0.4 ± 0.04 μg/l [saline] vs. 1.0 ± 0.1 μg/l [ghrelin]; P = 0.003).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
22 more claims
Create a free account to see all 62 claims and to verify the 34 references still open.
- Probably not a substantial claim. 29
- The quote only partly states this claim. 6
- It may state two separate claims as one. 10
Citations
Cites
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Ghrelin, an endogenous ligand for the growth hormone (GH) secretagogue receptor (GHS-R), stimulates GH and adrenocorticotropic hormone (ACTH) secretion (1) in addition to having orexigenic and gastrokinetic effects (2,3).”
BackgroundDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770
INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT*
Steele, R. (1959) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1959.tb44923.x · Cited by 1,670
The theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580
THE AMP-ACTIVATED/SNF1 PROTEIN KINASE SUBFAMILY: Metabolic Sensors of the Eukaryotic Cell?
Hardie, D. G., Carling, D., & Carlson, M. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.821 · Cited by 1,435
Ghrelin Strongly Stimulates Growth Hormone Release in Humans
Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimoto, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu, A., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7167 · Cited by 864 · cited 1×
“Ghrelin, an endogenous ligand for the growth hormone (GH) secretagogue receptor (GHS-R), stimulates GH and adrenocorticotropic hormone (ACTH) secretion (1) in addition to having orexigenic and gastrokinetic effects (2,3).”
BackgroundAMP-activated Protein Kinase Plays a Role in the Control of Food Intake
Andersson, U., Filipsson, K., Abbott, C. R., Woods, A., Smith, K., Bloom, S. R., Carling, D., & Small, C. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300557200 · Cited by 755
Kola, B., Hubina, E., Tucci, S. A., Kirkham, T. C., Garcia, E. A., Mitchell, S. E., Williams, L. M., Hawley, S. A., Hardie, D. G., Grossman, A. B., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500175200 · Cited by 472
Growth Hormone Secretagogue Binding Sites in Peripheral Human Tissues1
Papotti, M., Ghè, C., Cassoni, P., Catapano, F., Deghenghi, R., Ghigo, E., & Muccioli, G. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6846 · Cited by 410
Cited by
Items 101–157 of 157
Jejunal administration of glucose enhances acyl ghrelin suppression in obese humans
Tamboli, R. A., Sidani, R. M., Whitlock, A. E. G., Antoun, J., Isbell, J. M., Albaugh, V. L., & Abumrad, N. N. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00082.2016 · Cited by 11
Vestergaard, E. T., Møller, N., Andersen, R. F., Rittig, S., & Jørgensen, J. O. L. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0027 · Cited by 11
Self-citationZhang, H., Li, Q., Teng, Y., Lin, Y., Li, S., Qin, T., Chen, L., Huang, J., Zhai, H., Yu, Q., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.018 · Cited by 12
Can ghrelin improve appetite in uremic wasting?
Carrero, J. J., & Stenvinkel, P. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.171 · Cited by 11
Ghrelin Receptor in Energy Homeostasis and Obesity Pathogenesis
Li, Z., Li, Y., & Zhang, W. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386933-3.00002-9 · Cited by 11
Lotfi, A., Shahryar, H. A., Ghalehkandi, J. G., Kaiya, H., & Maheri‐Sis, N. (2011) · Czech Journal of Animal Science · doi:10.17221/2396-cjas · Cited by 10
Iwasaki, Y., Dezaki, K., Parmila, K., Kakei, M., & Yada, T. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.003 · Cited by 9
Ghrelin: a journey from GH secretagogue to regulator of metabolism
Chen, W., & Enriori, P. J. (2014) · Translational gastrointestinal cancer · Cited by 12
Ghrelin-GHSR-LEAP2 system in the pathophysiology of type 2 diabetes
Pu, Y., Yang, J., Li, W., Wen, Y., Zheng, C., Li, Y., Wu, L., Ming, Y., Zhao, C.-Y., & Chen, C. (2025) · iScience · doi:10.1016/j.isci.2025.113573 · Cited by 8
Serum ghrelin level is associated with cardiovascular risk score
Pop, D., Peter, P. S., Dǎdârlat, A., Sitar-Tăut, A., & Zdrenghea, M. (2015) · Romanian Journal of Internal Medicine · doi:10.1515/rjim-2015-0019 · Cited by 8
Goshadrou, F., Kazerouni, F., Mehranfard, N., & Sadeghi, B. (2015) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2015.07.001 · Cited by 8
Kärkkäinen, O. K., Farokhnia, M., Klåvus, A., Auriola, S. O. K., Lehtonen, M., Deschaine, S. L., Piacentino, D., Abshire, K. M., Jackson, S. N., & Leggio, L. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14719 · Cited by 7
St-Pierre, D. H., Benso, A. S., Gramaglia, E., Prodam, F., Lucatello, B. G., Gigliardi, V. R., Olivetti, I., Tomelini, M., & Broglio, F. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346604 · Cited by 6
Vestergaard, E. T., Jessen, N., Møller, N., & Jørgensen, J. O. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02601 · Cited by 6
Self-citationLauritzen, E. S., Jørgensen, J. O. L., Møller, N., Nielsen, S., & Vestergaard, E. T. (2020) · Clinical Endocrinology · doi:10.1111/cen.14290 · Cited by 6
Self-citationRegulation of peripheral tissue substrate metabolism by the gut-derived hormone ghrelin
Notaro, N. M., & Dyck, D. J. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100279 · Cited by 7
The endocrine effects of acylated and des-acylated ghrelin
St-Pierre, D., Cianflone, Comtois, Lalonde, & St-Pierre (2012) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s33480 · Cited by 5
Yamamoto, J., Onodera, H., Kaminaga, Y., Kayaba, Y., & Usui, M. (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j013 · Cited by 5
Dong, Y., Yin, J., Zhang, Y., & Chen, J. D. Z. (2021) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13367 · Cited by 5
The Ghrelin-LEAP2 System in Obesity and Diabetes: Pathophysiological Roles and Therapeutic Potential
Calero, I. V., Frühbeck, G., & Rodríguez, A. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00728-1 · Cited by 5
Gut hormones and Type 2 diabetes mellitus
Falinska, A. M., Tan, T., & Bloom, S. R. (2014) · Diabetes Management · doi:10.2217/dmt.14.47 · Cited by 4
Nass, R. M., Liu, J., Patrie, J. T., Pezzoli, S. S., Farhy, L. S., Gaylinn, B. D., & Thorner, M. O. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1210 · Cited by 4
Ghrelin- and GH-induced insulin resistance: no association with retinol-binding protein-4
Vestergaard, E. T., Krag, M. B., Poulsen, M. M., Pedersen, S. B., Møller, N., Jørgensen, J. O. L., & Jessen, N. (2013) · Endocrine Connections · doi:10.1530/ec-13-0019 · Cited by 4
Self-citationIs ghrelin a glucagon‐like peptide‐1 secretagogue?
Ueno, H., & Nakazato, M. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12431 · Cited by 2
Battillo, D. J., & Malin, S. K. (2023) · Metabolites · doi:10.3390/metabo13020137 · Cited by 2
Muhammad, A. A., Delhanty, P. J. D., Huisman, M., Visser, J. A., van der Lelij, A. J., & Neggers, S. J. C. M. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00147 · Cited by 3
Ghrelin: Neuropeptide Regulator of Metabolism
Enriori, P. J., Andrews, Z. B., & Cowley, M. A. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-903-7_6 · Cited by 2
Antunes, L. D. C., da Jornada, M. N., Elkfury, J. L., Foletto, K. C., & Bertoluci, M. C. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000002927 · Cited by 2
Okuro, K., Hashimoto, H., Morita, K., Noshi, Y., Kusushita, M., Ochiai, S., Utsu, Y., Kasayama, S., & Hashimoto, K. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4887-24 · Cited by 1
Luque, E. M., Carlini, V. P., Guantay, P., Machuca, D. A., Torres, P., Ramírez, N. D., Cantarelli, V. I., Ponzio, M., Castrogiovanni, D. C., Perelló, M., et al. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112608 · Cited by 1
Lund, L. H., Aizpurua, A. B., Bollano, E., Braun, O. B., Brouwer, J. L. P., Buikema, J. W., Cannata, A. N., Gardner, R. S., Handoko, M. L., Lang, C. C., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00904-9 · Cited by 1
Ghrelin in Cachexia Associated with End-Stage Renal Disease
Ashby, D. R., Choi, P., & Bloom, S. R. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-903-7_13 · Cited by 2
Ghrelin levels could be involved in the improvement of insulin resistance after bariatric surgery
Santiago‐Fernández, C., García‐Serrano, S., Tomé, M., Valdés, S., Ocaña-Wilhelmi, L., Rodríguez‐Cañete, A., Tinahones, F. J., García‐Fuentes, E., & Garrido‐Sánchez, L. (2017) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.08.011 · Cited by 1
Appetite Regulatory Peptides and Insulin Resistance
Orbetzova, M. M. (2012) · InTech eBooks · doi:10.5772/50977 · Cited by 5
Shahryar, H. A., & Lotfi, A. (2020) · Journal of the Hellenic Veterinary Medical Society · doi:10.12681/jhvms.22965 · Cited by 1
Regulation of Growth Hormone and Action (Secretagogues)
Kopchick, J. J., Martos‐Moreno, G. Á., Korbonits, M., Gaylinn, B. D., Nass, R. M., & Thorner, M. O. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00023-x · Cited by 1
Recent Trends in Bariatric and Metabolic Surgery
Weiner, R. A., El-Sayes, I., & Weiner, S. R. (2014) · Springer eBooks · doi:10.1007/978-3-319-13126-9_3
In vivo estimation of gluconeogenesis
Chacko, S. K. (2011) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Acylation state determines the action of ghrelin on energy and glucose metabolism
Heppner, K. M. (2013) · OhioLink ETD Center (Ohio Library and Information Network)
Ni, T., Zou, D., Huang, Q., Wang, Q.-J., Ding, C.-H., & Feng, Z.-K. (2013) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2012.00978
Mosa, R. (2017) · The University of Queensland · doi:10.14264/uql.2017.998 · Cited by 1
Kopchick, J. J., List, E. O., & Frohman, L. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00020-2
The Regulation of Adipose Tissue and Skeletal Muscle Substrate Metabolism by Ghrelin
Cervone, D. T. (2020) · The Atrium (University of Guelph)
Artene, D., Bordea, C. I., & Blidaru, A. (2016) · Romanian Medical Journal · doi:10.37897/rmj.2016.3.8
Current literature in diabetes
(2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.973
Microdialysis in Metabolic Research
Jansson, P. (2012) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-4815-0_12
Natural and Synthetic Growth Hormone Secretagogues
Motta, G., Allasia, S., Zavattaro, M., Ghigo, E., & Lanfranco, F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95972-5
Εταιρεία, Ε. Κ. (2020) · Journal of the Hellenic Veterinary Medical Society · doi:10.12681/jhvms.22961
Khalil, E. Z. I., Shaheen, K., Mohammed, E. M., & Mohamed, F. E. Z. A. (2023) · Egyptian Journal of Pathology · doi:10.4103/egjp.egjp_20_23
Natural and synthetic growth hormone secretagogues
Berton, A. M., Cuboni, D., Ghigo, E., & Gasco, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00237-5
The emerging role of epsilon cells in glucose homeostasis and lipostasis
Pavithra, N., Singh, S. A., Begum, R. F., Undela, K., Nirenjen, S., Keerthana, B., Singh, A., Mageswari, R., & Sabarathinam, S. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100672
Rôle et régulation de la protéine kinase AMPK au niveau intestinal
Harmel, É. (2012) · theses.fr (ABES) · doi:10.70675/0223f181zd1b3z4a87zadd0zd62495c76b6c
The effect of ghrelin on insulin sensitivity and beta-cell function after sleeve gastrectomy
Dichman, M.-L., Hedbäck, N., London, A., Jørgensen, N. B., Bojsen-Møller, K. N., Albrechtsen, N. J. W., van Hall, G., Kristiansen, V. B., Hartmann, B., Holst, J. J., et al. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00065.2026
BindingDB Entry 50045235: Small molecule ghrelin receptor inverse agonists and antagonists.
BindingDB (2016) · UC San Diego · doi:10.7270/q2542q74
Metadata
- Authors
- Vestergaard, E. T., Gormsen, L. C., Jessen, N., Lund, S., Hansen, T. K., Moller, N., & Jorgensen, J. O. L.
- Affiliations
- Aarhus University Hospital (DK)
- From Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus, Denmark
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-12-01
- Volume
- 57
- Issue
- 12
- Pages
- 3205-3210
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2584125
- OpenAlex
- W2105363738
- Semantic Scholar
- 0a7d7a10a4e399792726c97d988cf2d1e44e6736
- Cited by
- 156
- References
- 28
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 4 · 2017: 11 · 2016: 7 · 2015: 8 · 2014: 18 · 2013: 15 · 2012: 14
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Aarhus Universitetshospital
- World Anti-Doping Agency
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- ghrelin, insulin resistance, lipolysis, growth hormone, growth hormone secretagogue receptor, skeletal muscle, AMPK, cortisol, substrate metabolism, energy crisis
- MeSH terms
- Adrenocorticotropic Hormone, Double-Blind Method, Humans, Hydrocortisone, Hypopituitarism, Infusions, Intravenous, Insulin Resistance, Lipolysis, Male, Middle Aged, Reference Values, Growth Hormone, Signal Transduction, Cross-Over Studies, Ghrelin, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.